Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia

Canadian Journal of Infectious Diseases

Volumn 8, Issue 2, 1997, Pages 89-94

  Saginur, Raphael ^a   Garber, Gary ^b   Darling, Gail ^b   Shafran, Stephen ^b   Cameron, William ^b   Jones, Gwynne ^b   Auclair, Francois ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

Cephalosporins; Fluoroquinolones; Nosocomial infection; Pneumonia

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0030969864     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/973029     Document Type: Article

References (15)

1. Wenzel RP, ed. Prevention and Control of Nosocomial Infections, 2nd edn. Baltimore: Williams and Wilkins, 1993:v.
2. Wenzel RP. Hospital acquired pneumonia overview of the current state of the art for prevention and control. Eur J Clin Microbiol Infect Dis 1989;8:56-60.
3. Torres A, Aznor R, Gatell JM, et al. Incidence, risk and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Resp Dis 1990;142:523-8.
4. Craven DE, Steger KA, Duncan RA. Prevention and control of nosocomial pneumonia. In: Wenzel RP, ed. prevention and Control of Nosocomial Infection, 2nd edn. Baltimore: Williams and Wilkins, 1993:580-99.
5. Fagon JY, Chastre J, Hance AJ, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients. A cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-7.
6. Leu HS, Kaiser DL, Mori M, Woolson RF, Wenzel RP. Hospital acquired pneumonia; attributable mortality and morbidity. Am J Epidemiol 1989;129:1258-67.
7. Berk SL, Verghese A. Emerging pathogens in nosocomial pneumonia. Eur J Clin Microbiol Infect Dis 1989;8:11-4.
8. Pugin J, Auckenthalen R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and non-bronchoscopic 'blind' bronchoalveolar lavage fluid. Am Rev Respir Dis 1991;143:1121-9.
9. Garber GE, Auger P, Chan RMT, et al. A multicenter open comparative study of parenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections. Diagn Microbiol Infect Dis 1992;15:85-8.
10. Schentag JJ, Forrest A, Gos TF, et al. Ciprofloxacin eradicates respiratory tract bacteria more rapidly than cephalosporins in patients with nosocomial pneumonia. Drug 1993;45(Suppl):52.
11. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antlmicrob Agents Chemother 1994;38:547-57.
12. Mandell LA, Nicolle LE, Ronald AR, et al. A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. J Antimicrob Chemother 1987;20:95-107.
13. Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989;96:528-37.
14. Trenholme GM, Schmitt BA, Spear J, et al. Randomized trial of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med 1989;87(Suppl 5A):116S-8S.
15. Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother 1990;26(Suppl D):7-29.